ClinicalTrials.gg

Program

cipargamin

Also written as “KAE609”, “Cipargamin” and “KAE609 (Cipargamin)”.

In Novartis's pipeline, PfATP4 inhibitor. Its studies are mostly in Malaria · Malaria, Falciparum · Parasitemia, led by Novartis.

Furthest: phase 2, since Jan 30, 201210 company-led studies, 2 open or runningNext primary completion: Feb 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis102 open or runningphase 2since Jan 30, 2012Jan 30, 2012Feb 4, 2027phase 2 · NCT07811908
  • Named in Novartis’s own pipeline as KAE609 (cipargamin), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2012First study: phase 2 study in MalariaFirst studyNCT01524341 · 27 enrolled · Thailand
  2. Apr 17, 2013Phase 2 study in MalariaNCT01836458 · 25 enrolled · Vietnam
  3. May 21, 2013Phase 2 study in ParasitemiaNCT01860989 · 11 enrolled · Thailand, Vietnam
  4. Jul 23, 2015Phase 1 study in Malaria, FalciparumNCT02543086 · 8 enrolled · Australia
  5. Oct 27, 2017Phase 2 study in MalariaNCT03334747 · 188 enrolled · Gabon, Ghana, Mali and more
  6. Mar 23, 2020Phase 1 study in MalariaNCT04321252 · 57 enrolled · Belgium
  7. Dec 1, 2020Phase 2 study in MalariaNCT04675931 · 254 enrolled · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more
  8. Feb 17, 2023Phase 2 study in MalariaNCT05750628 · 327 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
  9. Nov 14, 2025Phase 2 study in Malaria, FalciparumNCT07235033 · 60 enrolled · Côte d’Ivoire, Gabon, Kenya
  10. Sep 4, 2026Phase 2 study in Malaria, FalciparumNCT07811908 · 120 planned · Burkina Faso, Côte d’Ivoire, Gabon and more

Ahead

  1. Feb 4, 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07811908

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“PfATP4 inhibitor”the company's pipeline, read by Claude · source
“P-type ATPase inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07811908Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more2RecruitingFeb 4, 2027120
NCT07235033Malaria, Falciparum · Côte d’Ivoire, Gabon, Kenya2CompletedMar 5, 202560
NCT05750628Malaria · Burkina Faso, Côte d’Ivoire, Gabon and more2RecruitingJun 9, 2026327
NCT04675931Malaria · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more2CompletedJul 24, 2025254
NCT04321252Malaria · Belgium1CompletedNov 10, 202057
NCT03334747Malaria · Gabon, Ghana, Mali and more2CompletedNov 23, 2019188
NCT02543086Malaria, Falciparum · Australia1TerminatedSep 20158
NCT01860989Parasitemia · Thailand, Vietnam2CompletedAug 201411
NCT01836458Malaria · Vietnam2CompletedMar 201525
NCT01524341Malaria · Thailand2CompletedJun 201227

How it is read

Names in the registry

  • “KAE609”, 11 entries
  • “Cipargamin”, 1 entry
  • “KAE609 (Cipargamin)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.